Human Protein Transformed into an mRNA “Delivery Vehicle”: NTHU Develops a Novel Carrier for Cancer Immunotherapy
Sustainable Development Goals
News Content
November 5, 2026 | 11:24 AM
United Daily News | By Wang Chun-chieh, Hsinchu
A research team at NTHU has developed a novel protein-based nanoparticle (PBNP) capable of autonomously packaging mRNA using PEG10, a naturally occurring human protein. Through genetic engineering, the team improved the production process and enhanced the efficiency of mRNA delivery into cancer cells. The study found that when PBNPs carrying immunotherapy-related mRNA were used in combination with chemotherapy drugs, they were more effective at inhibiting tumor growth and enhancing immune responses in animal models of colorectal cancer. The research was led by Yu-Cheng Hu, Chair Professor in the Department of Chemical Engineering at NTHU, and the findings have been published in the international journal Nature Communications.
NTHU explained that mRNA carries instructions for cells to produce proteins, but it is easily degraded and cannot readily enter cells on its own, making delivery vehicles necessary. Lipid nanoparticles (LNPs), which are commonly used today, generally require mRNA to be produced first, followed by multiple encapsulation procedures. In 2021, scientists discovered that PEG10, a naturally occurring human protein, can self-assemble into nanoparticles and preferentially package RNA containing specific recognition sequences. However, earlier techniques required expensive reagents to deliver the genes needed for nanoparticle production into cells, resulting in high costs and limited scalability.
Hu's research team adopted a different approach, using baculovirus (BV) to deliver the required genes into producer cells. After the cells produce PEG10 proteins and the engineered mRNA, the PEG10 proteins spontaneously assemble into nanoparticles and encapsulate the mRNA. Compared with conventional methods, the new production process reduces manufacturing costs, while increasing the mRNA delivery capacity per milliliter of PBNP formulation by 11.3 times. The resulting PBNPs can also maintain mRNA integrity and delivery functionality after seven months of refrigerated storage at 4°C.
Because different therapies require mRNA molecules of varying lengths, the team also demonstrated that the newly developed PBNPs can package mRNA sequences of at least 7,336 nucleotides. Nucleotides are the basic building blocks of RNA, and this length is sufficient to accommodate the instructions for producing multiple proteins within a single mRNA molecule.
Hu likened PBNPs to “delivery vehicles,” with mRNA serving as the cargo they transport. He explained that once the cargo has been loaded onto the PBNP platform, ensuring that it reaches its intended destination presents another research challenge. To address this, the team used genetic engineering to modify the nanoparticle surface by adding antibody fragments capable of recognizing the epidermal growth factor receptor (EGFR). After multiple adjustments to the component ratios, the team successfully developed PBNPs capable of both recognizing and entering cancer cells.
The paper's first author, Pin-Yen Chen, a doctoral student at the Institute of Chemical Engineering, noted that the team tested the delivery efficiency of PBNPs using mRNA that instructs cells to produce green fluorescent protein. Results showed that approximately 71% of laboratory-cultured colorectal cancer cells exhibited fluorescence. More than 60% of certain liver cancer and brain cancer cells also showed fluorescence. These results indicate that the mRNA successfully entered the cells and instructed them to produce proteins.
After confirming that PBNPs could deliver mRNA into cells, the team replaced the original mRNA with sequences encoding two immune-regulatory proteins, IL-12 and OX40L. Experiments showed that cancer cells could produce both proteins according to the delivered instructions. When co-cultured with immune cells, increased T-cell activation was also observed.
In animal models, researchers injected PBNPs directly into tumors and combined the treatment with the chemotherapy drug oxaliplatin. Compared with either treatment used alone, the combination therapy was more effective in suppressing tumor growth and enhancing immune responses. Preliminary observations also revealed no apparent acute toxicity.
The research has received recognition through Moderna's mRNA Innovation Research Award. Hu was also selected for the Y.S. Sun Innovation Chair Professorship in the field of nanotechnology. The team has now extended the technology to research on stem cells and tissue repair. Looking ahead, the researchers hope to use different mRNA instructions to guide cells in producing specific proteins, potentially expanding the technology into regenerative medicine and other fields.